Literature DB >> 17505058

Estrogen induces expression of BCAS3, a novel estrogen receptor-alpha coactivator, through proline-, glutamic acid-, and leucine-rich protein-1 (PELP1).

Anupama E Gururaj1, Shaohua Peng, Ratna K Vadlamudi, Rakesh Kumar.   

Abstract

We recently reported that the breast carcinoma amplified sequence-3 (BCAS3) gene is regulated by estrogen receptor (ER) alpha. However, the role of ERalpha coactivators in the regulation of BCAS3 expression remains unknown, and information regarding the function of the BCAS3 protein is lacking. Here, we define the contribution of ERalpha coactivators to BCAS3 regulation and identify BCAS3 itself as an ERalpha coactivator in breast cancer cells. We found that PELP1 (proline-, glutamic acid-, and leucine-rich protein-1), a newly described ERalpha coregulator, is recruited to BCAS3 chromatin and activates its expression. Analysis of the BCAS3 sequence for functional motifs and evidence from biochemical fractionation suggested that BCAS3 acts as a transcriptional coactivator. Results from chromatin immunoprecipitation, reporter assays, and expression studies further validated the coactivator function of BCAS3 for ERalpha. BCAS3 physically associated with histone H3 and histone acetyltransferase complex protein P/CAF (p300/CBP-associated factor) and possessed histone acetyltransferase activity. Unexpectedly, BCAS3 required PELP1 to function as a coactivator in ERalpha transactivation activity. In brief, these results highlight a mechanism whereby ERalpha activation triggers a positive feedback loop leading to signal amplification in the cell.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17505058     DOI: 10.1210/me.2006-0514

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  8 in total

Review 1.  Minireview: Deciphering the Cellular Functions of PELP1.

Authors:  Preethi Ravindranathan; Carol A Lange; Ganesh V Raj
Journal:  Mol Endocrinol       Date:  2015-07-09

2.  PELP1 oncogenic functions involve alternative splicing via PRMT6.

Authors:  Monica Mann; Yi Zou; Yidong Chen; Darrell Brann; Ratna Vadlamudi
Journal:  Mol Oncol       Date:  2013-12-30       Impact factor: 6.603

Review 3.  Nuclear receptor coregulators in cancer biology.

Authors:  Bert W O'Malley; Rakesh Kumar
Journal:  Cancer Res       Date:  2009-10-20       Impact factor: 12.701

Review 4.  PELP1: a review of PELP1 interactions, signaling, and biology.

Authors:  Brian J Girard; Andrea R Daniel; Carol A Lange; Julie H Ostrander
Journal:  Mol Cell Endocrinol       Date:  2013-08-08       Impact factor: 4.102

Review 5.  Derailed estrogen signaling and breast cancer: an authentic couple.

Authors:  Bramanandam Manavathi; Oindrilla Dey; Vijay Narsihma Reddy Gajulapalli; Raghavendra Singh Bhatia; Suresh Bugide; Rakesh Kumar
Journal:  Endocr Rev       Date:  2012-09-04       Impact factor: 19.871

6.  Prognostic significance of proline, glutamic acid, leucine rich protein 1 (PELP1) in triple-negative breast cancer: a retrospective study on 129 cases.

Authors:  Yanzhi Zhang; Jiali Dai; Keely M McNamara; Bing Bai; Mumu Shi; Monica S M Chan; Ming Liu; Hironobu Sasano; Xiuli Wang; Xiaolei Li; Lijuan Liu; Ying Ma; Shuwen Cao; Yanchun Xing; Baoshan Zhao; Yinli Song; Lin Wang
Journal:  BMC Cancer       Date:  2015-10-15       Impact factor: 4.430

7.  Systems level-based RNAi screening by high content analysis identifies UBR5 as a regulator of estrogen receptor-α protein levels and activity.

Authors:  M J Bolt; F Stossi; A M Callison; M G Mancini; R Dandekar; M A Mancini
Journal:  Oncogene       Date:  2014-01-20       Impact factor: 9.867

8.  Regulation of estrogen receptor signaling in breast carcinogenesis and breast cancer therapy.

Authors:  Zhuan Zhou; Joe X Qiao; Amit Shetty; George Wu; Yi Huang; Nancy E Davidson; Yong Wan
Journal:  Cell Mol Life Sci       Date:  2014-04       Impact factor: 9.207

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.